The latest news on MS treatments, research and specialist services.
MS Trust news
News from the MS Trust
Views and comment
MS Trust staff, MS health professionals and people with MS offer their perspectives on hot topics in the world of MS
Our free, quarterly newsletter for people with multiple sclerosis, their family and friends and supporters of the MS Trust.
Read our latest news
- Gilenya and Betaferon compared
- Pain prevalence and treatment
- Cold water in the mouth helps heat sensitivity
- Benefit reassessment concerns
- Review of the year - MS in America
Larissa Thomas was diagnosed with MS in July last year. Here she talks tattoos, smiling through the pain and why she’s determined to make the best of things.
- Diet may improve MS
- Laquinimod trial for PPMS unsuccessful
- Epilepsy and MS
- Stem cell therapy consensus report
Paralympic champion Kadeena Cox, who was diagnosed with MS in 2014, talks sport, MS and the people who inspire her.
- Shortage of neurology services
- Diet affects gut bacteria and modulates immune system
- Cognitive symptoms in early-stage MS
- High number of people with MS turned down for PIP
- Biotin may affect medical tests
The outstanding work of MS specialist nurses, neurologists, allied health professionals and multi-disciplinary teams from across the UK was celebrated at the third annual QuDoS in MS recognition programme.
- Mark Lewis and stem cells
- Self-management may help mood
- CCSVI trial disappointing
- Why smoking is bad for people with MS
- Ocrevus licensed for relapsing and progressive MS
- Gilenya effective for children with MS
- Social care failing people with disabilities
- Wii a useful way to exercise
School friends Emma and Marc took on the Descente London Duathlon this September, raising £700 in sponsorship.
The European Medicines Agency recommends licensing for ocrelizumab (Ocrevus) for treating active relapsing and early primary progressive MS.
Reports of studies presented at the ECTRIMS meeting that took place from 25-28 October 2017. Topics include research into existing and new drugs for relapsing and progressive MS and lifestyle factors in MS.
NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) immediately.
This year the MS Trust has been working with city philanthropists The October Club to raise money to pioneer a new role in MS teams: Advanced MS Champions. But how will our new Champions make a difference? We spoke to Lyn, who was diagnosed with MS over 20 years ago.
Actress Jamie-Lynn Sigler, who was diagnosed with MS aged 20, has recently been trying to remove some of the stigma around walking sticks by talking on social media about how she uses hers. We asked our Facebook community for their advice to people who have just started to use a stick.
Many people with MS live by the motto “I may have MS but MS doesn’t have me” and are determined not to let the disease define them. But what if you find that your MS means you don’t feel comfortable in your own clothes any more, and can’t find anything practical you do like? Here we speak to Helen and Hannah Dunk who have launched a new fashion label for women in wheelchairs, and Katie Ellis, founder of adaptive clothing company The Able Label.
We are thrilled to announce that our corporate partner Constructive Space has raised an incredible £17,288 to support people living with MS.
- Ibudilast trial show benefit in progressive MS
- Gilenya effective as treatment for teens with MS
- Zinbryta liver damage restrictions
- Having other health conditions delays MS diagnosis
- The benefits of running for a woman with MS
Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and Wales.